SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing heightened volatility, with community discussions focused on the potential impact of recent market liquidations and macroeconomic factors like tariff concerns.  Traders are debating potential support levels and whether this pullback presents a buying opportunity or signals a deeper correction.  Meme coins like $1DOG and $CHINAU are gaining traction, while some traders are wary of shitcoins in general.

1 dog can change your life

$1DOG is trending amid community excitement, particularly among Phantom Wallet users, with many highlighting its 'magic meme energy'. Conversations suggest a growing and active community is rallying behind $1DOG, with many anticipating a potential surge.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight activity around meme tokens like $1DOG, $CHINAU, and $UPDOG, particularly within the Phantom Wallet ecosystem. There's also increasing discussion around Solana's potential for tokenized stock trading and anticipation for a possible SOL ETF approval. Despite recent market volatility, some community members express long-term bullish sentiment and advocate for staking.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending amid community excitement, with many noting its green performance in a sea of red for the broader crypto market. The community is buzzing about a potential partnership with Coinbase's Spindl and highlighting Hydrex as a competitor to $AERO. Some users suggest it has substantial upside potential due to its relatively low market cap.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending amid discussions about a recent market dip and potential buying opportunities, with some community members speculating about orchestrated market manipulation.  Conversations revolve around identifying key resistance levels and predictions for future price movements, while others are discussing the potential impact of upcoming news and long-term prospects for the crypto. There is also discussion about meme coins and specific partnerships within the HBAR ecosystem.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer's cryptocurrency, ICP, is experiencing a surge in community interest, with many users expressing excitement about its current price and potential for long-term gains, while some suggest there is coordinated effort to suppress the coin. The community is actively discussing entry points, staking rewards, and the potential impact of upcoming developments like Caffeine AI, alongside comparing ICP to other altcoins and expressing bullish sentiment despite past performance. Concerns persist around the project's leadership, market manipulation, and broader adoption, with some community members actively expressing frustration around the project's performance.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

PTGX is trending amid reports of positive clinical trial results, specifically related to a Phase 2b study, leading to significant price movement. Community discussions revolve around the potential for further clinical advancements and speculation regarding a possible acquisition. The company's pipeline and existing partnerships, including one with Johnson & Johnson, add to the bullish sentiment.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending as investors discuss its undervaluation compared to competitors and potential benefits from tariffs driving wealth to Singapore, where it has a strong presence. The community is debating whether it is a buying opportunity, with some citing strong fundamentals and growth potential, while others express concern over its performance and connection to Chinese markets. Recent options activity and technical analysis are also fueling the conversation.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to speculation of a potential short squeeze, driven by its low float and recent price action; the community is actively watching key breakout levels, anticipating a significant upward move if resistance is broken. Some traders are pointing to the stock's tight float and recent after-hours activity as indicators of a possible parabolic run, while others suggest caution due to past trading patterns.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Oncology ($CGEM) is trending due to community interest in its pipeline and recent data presentations, particularly around zipalertinib. Discussions involve institutional buying and the potential of CLN-978 in autoimmune diseases. Some traders are noting the company's cash position relative to its market cap, while analysts have reiterated buy ratings.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

Equity

Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11.&nbsp;The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment, with conversations on Stocktwits turning more skeptical.Morgan Stanley cited a “more measured launch” for nexiguran ziclumeran, Intellia’s lead therapy for transthyretin amyloidosis, a rare and progressive heart disorder.&nbsp;The brokerage also pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.The analyst noted growing competition from non-gene-editing therapies, which could challenge Intellia’s position as a leader in “in vivo” CRISPR editing.&nbsp;Intellia’s approach reportedly delivers CRISPR components directly into the body to modify DNA, bypassing the need to engineer treatments from a patient’s cells.Earlier this month, Intellia announced a 27% workforce reduction and plans to halt&nbsp;the development of NTLA-3001 and some early-stage research programs.The company expects to incur $8 million in restructuring charges in the first quarter but believes the changes, combined with its cash balance of $862 million at the end of the fourth quarter, will extend its cash runway into the first half of 2027.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NTLA_sentiment_and_message_volume_Jan_27_414be9f90a.png" alt="NTLA sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>NTLA sentiment and message volume Jan 27 as of 11:40 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bearish’ following the downgrade.&nbsp;<stembedurl>https://stocktwits.com/KimAntony/message/601612137</stembedurl><stembedurl>https://stocktwits.com/CharlesEscobar/message/601578564</stembedurl><a href="https://stocktwits.com/symbol/NTLA">Intellia’s stock</a> has a high short interest of 21.3% and has lost nearly 60% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

Shares of Tempus AI climbed more than 5% on Thursday afternoon, poised for their longest winning streak since August 2024.&nbsp;The healthcare technology company has surged from $35 to $53 in just three days, drawing significant retail attention.On Tuesday, Tempus&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tempus-ai-stock-surges-on-ai-enabled-healthcare-app-launch-pelosi-buy/chbdxNURFV">introduced</a> an artificial intelligence-powered healthcare concierge app for patients, sparking optimism about its potential in the growing AI healthcare space.A routine stock trading disclosure revealed former House Speaker Nancy Pelosi purchased 50 call options on Tempus, expiring in January 2026 with a $20 strike price. This added to the speculative excitement surrounding the stock.President Donald Trump’s announcement of “Stargate,” a joint venture with OpenAI, Oracle, and SoftBank to invest billions in domestic AI development, further fueled investor enthusiasm for AI-related stocks like Tempus.While Tempus managed to see a 186% growth in retail followers on Stocktwits since Tuesday, sentiment shifted from ‘extremely bullish’ to ‘bearish’ by Thursday afternoon.&nbsp;The platform saw a spike in pessimistic messages, with users criticizing the frenzy over Pelosi’s involvement and some reporting profit-taking after the stock’s rally.<stembedurl>https://stocktwits.com/WallStreetBetzBoss/message/601130338</stembedurl><stembedurl>https://stocktwits.com/HIGHTABLETRADES/message/601134687</stembedurl><stembedurl>https://stocktwits.com/Harvz90/message/601192109</stembedurl>A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.&nbsp;That caused a brief dip in the stock earlier on Thursday, although it rebounded later in the session.Tempus AI has a short interest of 5.5%, according to Koyfin data.Shares of the company have gained over 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

Options Alert: Should Investors Jump on This Cathie Wood-Owned Life Sciences Specialist?

While proteomics firms Quantum-Si has made waves recently, QSI stock might not be the long-term play value investors are seeking.

Intellia Therapeutics, Inc. ($NTLA) shares plunged hard on Thursday after the small-cap, clinical-stage biotech reported results from mid-stage study results of its CRISPR-based gene-editing therapy codenamed NTLA-2002 in patients with hereditary angioedema (HAE).HAE is a rare genetic disorder that manifests as severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body. The condition could lead to potentially life-threatening swelling attacks.&nbsp;The disorder has no curative therapies but current preventive therapies have to be administered lifelong.&nbsp;Intellia said the results from the Phase 2 study showed NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion.&nbsp;Among the findings from the study are:<ul><li>Both dose levels tested (25 mg and 50 mg) reduced mean monthly attacks, with the latter dose resulting in a 77% reduction during weeks 1-16 and 81% reduction in weeks 5-16.</li><li>Eight of the 11 patients in the 50 mg arm were completely attack free following one-time infusion</li><li>Safety and tolerability profiles were encouraging.</li></ul>“We are highly encouraged by these results, which we believe sets NTLA-2002 apart from other prophylaxis treatments. What was previously an unimaginable potential to be free of chronic therapy is one step closer to becoming a reality for the HAE community,” said John Leonard, CEO of Intellia.The company said it has selected the 50 mg formulation for evaluation in the global Phase 3 study dubbed ‘HALEO.’ Screening for the study is currently ongoing, it said.HAE therapeutics market was at $4.1 billion in 2023 and is estimated to grow at 9.2% compounded annual growth rate between 2024 and 2032,<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gminsights.com/industry-analysis/hereditary-angioedema-therapeutics-market"> according</a> to Global Market Insights.The negative reaction could be due to the “buy-the-rumor, sell-the-news” phenomenon as the stock tacked on about 17%&nbsp;gains from a near-term (Oct. 10) low of $17.09.<figure class="image"><a href="https://stocktwits.com/symbol/NTLA"><img style="aspect-ratio:633/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/intellia_sentiment_b2935066a6.png" alt="intellia-sentiment.png" width="633" height="142"></a><figcaption>NTLA sentiment and message volume October 24, 2024, as of 11:05 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail trader sentiment was ‘extremely bearish’ (21/100), reversing from ‘bullish’ mood a day ago, with message volume spiking to ‘extremely high.’At 11:05 am ET, the stock was down 19.51% at $16.05, although off the day’s low of $15.52, which marked the lowest level in over four years.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ups-earnings-and-revenue-beat-estimates/cJ218XiR7Q">UPS Stock Soars Pre-Market, Keeps Retail Bullish As Q3 Beat Pleases Wall Street</a>For updates and corrections email newsroom@stocktwits.com

Intellia's mid-stage gene-editing therapy study results did not impress investors.

Intellia Stock Plunges To 4-Year Low Despite Promising Mid-Stage Study Results For Rare Genetic Disorder Therapy, Retail Sentiment Dips

Intellia stock tumbled to its lowest level in over four years as investors shrugged off what the company touted as promising results for its hereditary angioedema investigational gene-editing therapy.

Shares of Moderna plunged nearly 17% during the pre-market session after the company trimmed its full-year forecast. It cited low EU sales in 2024, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the U.S.Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion from its respiratory franchise compared to previous guidance of $4 billion.Following the announcement, retail sentiment dipped into ‘extremely bearish’ territory (16/100) souring further from yesterday’s ‘bearish’ reading.<figure class="image"><a href="https://stocktwits.com/symbol/MRNA"><img style="aspect-ratio:786/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_33_23_AM_44abb6c210.png" alt="Moderna sentiment meter as of 8:47 a.m. on August 01, 2024" width="786" height="224"></a><figcaption>Moderna sentiment meter as of 8:47 a.m. on August 01, 2024</figcaption></figure>On a positive note, the vaccine-maker reported an earnings loss of $3.33 during the second quarter versus an estimated loss of $3.39. Revenue came in at $241 million compared to a forecast of $132 million. Despite beating the analyst estimate, revenue declined 30% year-over-year (YoY) weighed down by decreased sales of the company's COVID-19 vaccine.Stéphane Bancel, Chief Executive Officer of Moderna stated that the firm has significantly lowered its operating costs during the second quarter. “We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.,” he said.Bancel stated the firm is involved in discussions with governments across Europe but some of them have pointed toward a tight budget restraining their capacity to buy more vaccines. The firm reportedly expects to see sales growth by 2025 and hit a breakeven position by 2026.Retail investors aren’t happy with the full-year guidance trim and the company’s efforts on the Covid vaccine given that its demand remains uncertain. One Stocktwits user expressed his ‘bearish’ view by stating that Moderna lowered its already lowered guidance, a sign it still has work to do in sufficiently diversifying its revenue streams.<figure class="image"><a href="https://stocktwits.com/JonOliNYC2020/message/581403885"><img style="aspect-ratio:794/160;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_01_at_9_34_35_AM_028dd1393e.png" alt="Stocktwits user JonOliNYC2020's post on Moderna stock " width="794" height="160"></a><figcaption>Stocktwits user JonOliNYC2020's post on Moderna stock&nbsp;</figcaption></figure>

Moderna now expects 2024 net product sales between $3.00 billion and $3.50 billion

Moderna Surpassed Q2 Earnings Estimates: Here’s Why Retail Sentiment Is ‘Extremely Bearish’ And The Stock Is Down 17%

While the vaccine-maker’s revenues beat estimates and its loss narrowed, management slashed its full-year sales forecast. Moreover, its struggles with EU sales and uncertainty over COVID vaccine demand remain key concerns for investors.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARKG News

ARKGARK Investment Management LLC - ARK Genomic Revolution ETF